Cargando…

Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is associated with increased expression of cyclin-dependent kinase inhibitors such as p16 and p21, and subsequent induction of cell cycle arrest, cellular senescence, and pro-fibrotic gene expression. We sought to link p16-expression with a diagnosis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Keow, Jonathan, Cecchini, Matthew J., Jayawardena, Nathashi, Zompatori, Maurizio, Joseph, Mariamma G., Mura, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175499/
https://www.ncbi.nlm.nih.gov/pubmed/35672770
http://dx.doi.org/10.1186/s12931-022-02067-w
_version_ 1784722468932419584
author Keow, Jonathan
Cecchini, Matthew J.
Jayawardena, Nathashi
Zompatori, Maurizio
Joseph, Mariamma G.
Mura, Marco
author_facet Keow, Jonathan
Cecchini, Matthew J.
Jayawardena, Nathashi
Zompatori, Maurizio
Joseph, Mariamma G.
Mura, Marco
author_sort Keow, Jonathan
collection PubMed
description BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is associated with increased expression of cyclin-dependent kinase inhibitors such as p16 and p21, and subsequent induction of cell cycle arrest, cellular senescence, and pro-fibrotic gene expression. We sought to link p16-expression with a diagnosis of IPF or other fibrotic interstitial lung diseases (ILDs), radiographic pattern, senescent foci-specific gene expression, antifibrotic therapy response, and lung transplant (LTx)-free survival. METHODS: Eighty-six cases of fibrosing ILD were identified with surgical lung biopsy. Immunohistochemistry for p16 was performed on sections with the most active fibrosis. p16-positive foci (loose collection of p16-positive fibroblasts with overlying p16-positive epithelium) were identified on digital slides and quantified. Cases were scored as p16-low (≤ 2.1 foci per 100 mm(2)) or p16-high (> 2.1 foci per 100 mm(2)). Twenty-four areas including senescent foci, fibrotic and normal areas were characterized using in situ RNA expression analysis with digital spatial profiling (DSP) in selected cases. RESULTS: The presence of p16-positive foci was specific for the diagnosis of IPF, where 50% of cases expressed any level of p16 and 26% were p16-high. There was no relationship between radiographic pattern and p16 expression. However, there was increased expression of cyclin-dependent kinase inhibitors, collagens and matrix remodeling genes within p16-positive foci, and cases with high p16 expression had shorter LTx-free survival. On the other hand, antifibrotic therapy was significantly protective. DSP demonstrated that fibroblastic foci exhibit transcriptional features clearly distinct from that of normal-looking and even fibrotic areas. CONCLUSIONS: We demonstrated the potential clinical applicability of a standardized quantification of p16-positive fibroblastic foci. This method identifies an IPF phenotype associated with foci-specific upregulation of senescence-associated and matrix remodeling gene expression. While these patients have reduced LTx-free survival, good response to antifibrotic therapies was observed in those who were treated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02067-w.
format Online
Article
Text
id pubmed-9175499
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91754992022-06-09 Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival Keow, Jonathan Cecchini, Matthew J. Jayawardena, Nathashi Zompatori, Maurizio Joseph, Mariamma G. Mura, Marco Respir Res Research BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is associated with increased expression of cyclin-dependent kinase inhibitors such as p16 and p21, and subsequent induction of cell cycle arrest, cellular senescence, and pro-fibrotic gene expression. We sought to link p16-expression with a diagnosis of IPF or other fibrotic interstitial lung diseases (ILDs), radiographic pattern, senescent foci-specific gene expression, antifibrotic therapy response, and lung transplant (LTx)-free survival. METHODS: Eighty-six cases of fibrosing ILD were identified with surgical lung biopsy. Immunohistochemistry for p16 was performed on sections with the most active fibrosis. p16-positive foci (loose collection of p16-positive fibroblasts with overlying p16-positive epithelium) were identified on digital slides and quantified. Cases were scored as p16-low (≤ 2.1 foci per 100 mm(2)) or p16-high (> 2.1 foci per 100 mm(2)). Twenty-four areas including senescent foci, fibrotic and normal areas were characterized using in situ RNA expression analysis with digital spatial profiling (DSP) in selected cases. RESULTS: The presence of p16-positive foci was specific for the diagnosis of IPF, where 50% of cases expressed any level of p16 and 26% were p16-high. There was no relationship between radiographic pattern and p16 expression. However, there was increased expression of cyclin-dependent kinase inhibitors, collagens and matrix remodeling genes within p16-positive foci, and cases with high p16 expression had shorter LTx-free survival. On the other hand, antifibrotic therapy was significantly protective. DSP demonstrated that fibroblastic foci exhibit transcriptional features clearly distinct from that of normal-looking and even fibrotic areas. CONCLUSIONS: We demonstrated the potential clinical applicability of a standardized quantification of p16-positive fibroblastic foci. This method identifies an IPF phenotype associated with foci-specific upregulation of senescence-associated and matrix remodeling gene expression. While these patients have reduced LTx-free survival, good response to antifibrotic therapies was observed in those who were treated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02067-w. BioMed Central 2022-06-07 2022 /pmc/articles/PMC9175499/ /pubmed/35672770 http://dx.doi.org/10.1186/s12931-022-02067-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Keow, Jonathan
Cecchini, Matthew J.
Jayawardena, Nathashi
Zompatori, Maurizio
Joseph, Mariamma G.
Mura, Marco
Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
title Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
title_full Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
title_fullStr Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
title_full_unstemmed Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
title_short Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
title_sort digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175499/
https://www.ncbi.nlm.nih.gov/pubmed/35672770
http://dx.doi.org/10.1186/s12931-022-02067-w
work_keys_str_mv AT keowjonathan digitalquantificationofp16positivefociinfibroticinterstitiallungdiseaseisassociatedwithaphenotypeofidiopathicpulmonaryfibrosiswithreducedsurvival
AT cecchinimatthewj digitalquantificationofp16positivefociinfibroticinterstitiallungdiseaseisassociatedwithaphenotypeofidiopathicpulmonaryfibrosiswithreducedsurvival
AT jayawardenanathashi digitalquantificationofp16positivefociinfibroticinterstitiallungdiseaseisassociatedwithaphenotypeofidiopathicpulmonaryfibrosiswithreducedsurvival
AT zompatorimaurizio digitalquantificationofp16positivefociinfibroticinterstitiallungdiseaseisassociatedwithaphenotypeofidiopathicpulmonaryfibrosiswithreducedsurvival
AT josephmariammag digitalquantificationofp16positivefociinfibroticinterstitiallungdiseaseisassociatedwithaphenotypeofidiopathicpulmonaryfibrosiswithreducedsurvival
AT muramarco digitalquantificationofp16positivefociinfibroticinterstitiallungdiseaseisassociatedwithaphenotypeofidiopathicpulmonaryfibrosiswithreducedsurvival